Chao Liu1, Zhao-Yan Cheng1, Qing-Peng Xia1, Yu-Hui Hu1, Chen Wang1, Ling He2. 1. Department of Pharmacology, China Pharmaceutical University, No. 24 Tong Jia Xiang, Nanjing, 210009, Jiang Su Province, China. 2. Department of Pharmacology, China Pharmaceutical University, No. 24 Tong Jia Xiang, Nanjing, 210009, Jiang Su Province, China. heling92@hotmail.com.
Abstract
RATIONALE: Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by progressive cognitive dysfunction and memory impairment. G protein-coupled receptor 40 (GPR40) is expressed in brain in addition to periphery and is associated with cognitive function such as space orientation, memory, and learning. However, the effects and mechanisms of GPR40 agonist in improving the AD progression remain largely unknown. OBJECTIVES: The present study aimed to investigate the therapeutic effects and mechanisms of a potent and selective GPR40 agonist TAK-875 on the APPswe/PS1dE9 mice. RESULTS: The results showed that intracerebroventricular administration of TAK-875 significantly rescued cognitive deficits in APPswe/PS1dE9 mice, and these effects may be mediated by the regulation of phospholipase C/protein kinase C signaling pathway, which enhanced α-secretase ADAM10 activity, promoted amyloid precursor protein non-amyloidogenic processing pathway, and reduced β-amyloid production. CONCLUSIONS: These results suggest that GPR40 may be a potential therapeutic target for AD, and GPR40 agonists may become promising AD drugs in the future.
RATIONALE: Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by progressive cognitive dysfunction and memory impairment. G protein-coupled receptor 40 (GPR40) is expressed in brain in addition to periphery and is associated with cognitive function such as space orientation, memory, and learning. However, the effects and mechanisms of GPR40 agonist in improving the AD progression remain largely unknown. OBJECTIVES: The present study aimed to investigate the therapeutic effects and mechanisms of a potent and selective GPR40 agonist TAK-875 on the APPswe/PS1dE9 mice. RESULTS: The results showed that intracerebroventricular administration of TAK-875 significantly rescued cognitive deficits in APPswe/PS1dE9 mice, and these effects may be mediated by the regulation of phospholipase C/protein kinase C signaling pathway, which enhanced α-secretase ADAM10 activity, promoted amyloid precursor protein non-amyloidogenic processing pathway, and reduced β-amyloid production. CONCLUSIONS: These results suggest that GPR40 may be a potential therapeutic target for AD, and GPR40 agonists may become promising AD drugs in the future.
Authors: Celia P Briscoe; Andrew J Peat; Stephen C McKeown; David F Corbett; Aaron S Goetz; Thomas R Littleton; David C McCoy; Terry P Kenakin; John L Andrews; Carina Ammala; James A Fornwald; Diane M Ignar; Stephen Jenkinson Journal: Br J Pharmacol Date: 2006-05-15 Impact factor: 8.739
Authors: Celia P Briscoe; Mohammad Tadayyon; John L Andrews; William G Benson; Jon K Chambers; Michelle M Eilert; Catherine Ellis; Nabil A Elshourbagy; Aaron S Goetz; Dana T Minnick; Paul R Murdock; Howard R Sauls; Usman Shabon; Lisa D Spinage; Jay C Strum; Philip G Szekeres; Kong B Tan; James M Way; Diane M Ignar; Shelagh Wilson; Alison I Muir Journal: J Biol Chem Date: 2002-12-19 Impact factor: 5.157
Authors: Daiane F Engel; Vanessa C D Bobbo; Carina S Solon; Guilherme A Nogueira; Alexandre Moura-Assis; Natalia F Mendes; Ariane M Zanesco; Athanasios Papangelis; Trond Ulven; Licio A Velloso Journal: Sci Rep Date: 2020-07-06 Impact factor: 4.379